<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Urol Ann</journal-id><journal-id journal-id-type="iso-abbrev">Urol Ann</journal-id><journal-id journal-id-type="publisher-id">UA</journal-id><journal-title-group><journal-title>Urology Annals</journal-title></journal-title-group><issn pub-type="ppub">0974-7796</issn><issn pub-type="epub">0974-7834</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29416281</article-id><article-id pub-id-type="pmc">5791464</article-id><article-id pub-id-type="publisher-id">UA-10-82</article-id><article-id pub-id-type="doi">10.4103/UA.UA_36_17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparative efficacy of tamsulosin versus tadalafil as medical expulsive therapy for distal ureteric stones</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goyal</surname><given-names>Suresh Kumar</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Vikash</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Pandey</surname><given-names>Himanshu</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Chhabra</surname><given-names>Mahaveer Kumar</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Aggarwal</surname><given-names>Satinder Pal</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Bhat</surname><given-names>Amilal</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib></contrib-group><aff id="aff1">Department of Urology, Dr. S. N. Medical College, Jodhpur, Rajasthan, India</aff><aff id="aff2"><label>1</label>Department of Urology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India</aff><aff id="aff3"><label>2</label>Department of Urology, S.M.S. Medical College, Jaipur, Rajasthan, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Suresh Kumar Goyal, Department of Urology, All India Institute of Medical Sciences, Jodhpur - 342 001, Rajasthan, India. E-mail: <email xlink:href="sureshgoyal7@gmail.com">sureshgoyal7@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2018</year></pub-date><volume>10</volume><issue>1</issue><fpage>82</fpage><lpage>86</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: © 2018 Urology Annals</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3743" xml_f="3753" txt_i="11" txt_f="21">Objective:</offsets></title><p><offsets xml_i="3764" xml_f="3913" txt_i="22" txt_f="171">The objective of this study was to compare the relative efficacy of tamsulosin and tadalafil as medical expulsive therapy for distal ureteric stones.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3944" xml_f="3965" txt_i="173" txt_f="194">Patients and Methods:</offsets></title><p><offsets xml_i="3976" xml_f="4615" txt_i="195" txt_f="831">This was a prospective study performed between December 2014 and February 2016. A total of 123 adult patients (&gt;18 years of age) presenting with distal ureteric stones sized 6–10 mm were randomized to treatment with tamsulosin 0.4 mg once daily (Group A) or tadalafil10 mg once daily (Group B). Therapy was given for a maximum of 4 weeks. The stone expulsion rate was the primary endpoint. Time to stone expulsion, number of colic episodes, analgesic use, number of hospital visits for pain, endoscopic treatment, and adverse effects of the drugs were noted. Statistical analyses were done using Fisher's exact test and Chi-square test.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4646" xml_f="4654" txt_i="833" txt_f="841">Results:</offsets></title><p><offsets xml_i="4665" xml_f="4898" txt_i="842" txt_f="1075">A total of 61 patients were included in tamsulosin group and 62 patients in tadalafil group. A statistically insignificant difference was found for stone clearance rate between both groups as a whole (Group A-73.77%, Group B-69.35%, </offsets><italic><offsets xml_i="4906" xml_f="4907" txt_i="1075" txt_f="1076">P</offsets></italic><offsets xml_i="4916" xml_f="4993" txt_i="1076" txt_f="1153"> = 0.690) as well as when we considered both subgroups (A1-78.05%, B1-75.0%, </offsets><italic><offsets xml_i="5001" xml_f="5002" txt_i="1153" txt_f="1154">P</offsets></italic><offsets xml_i="5011" xml_f="5041" txt_i="1154" txt_f="1184"> = 0.802; A2-65.0%, B2-55.6%, </offsets><italic><offsets xml_i="5049" xml_f="5050" txt_i="1184" txt_f="1185">P</offsets></italic><offsets xml_i="5059" xml_f="5331" txt_i="1185" txt_f="1454"> = 0.741). All the primary and secondary outcome measures were more in favour of stones ≤8 mm size than stones &gt;8 mm size. No statistical difference was found for adverse drug effects except for retrograde ejaculation, which was significantly high in tamsulosin group (</offsets><italic><offsets xml_i="5339" xml_f="5340" txt_i="1454" txt_f="1455">P</offsets></italic><offsets xml_i="5349" xml_f="5362" txt_i="1455" txt_f="1465"> &lt; 0.001).</offsets></p></sec><sec id="st4"><title><offsets xml_i="5393" xml_f="5404" txt_i="1467" txt_f="1478">Conclusion:</offsets></title><p><offsets xml_i="5415" xml_f="5553" txt_i="1479" txt_f="1617">This study showed that although tamsulosin is more effective for stone clearance than tadalafil, but this difference was not significant (</offsets><italic><offsets xml_i="5561" xml_f="5562" txt_i="1617" txt_f="1618">P</offsets></italic><offsets xml_i="5571" xml_f="5581" txt_i="1618" txt_f="1628"> = 0.690).</offsets></p></sec></abstract><kwd-group><kwd>Lower ureteric stones</kwd><kwd>medical expulsive therapy</kwd><kwd>tadalafil</kwd><kwd>tamsulosin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5804" xml_f="5816" txt_i="1637" txt_f="1649">INTRODUCTION</offsets></title><p><offsets xml_i="5827" xml_f="6135" txt_i="1650" txt_f="1958">Medical expulsive therapy (MET) is an established noninvasive treatment modality for distal ureteric calculi. Varied combinations of medical treatments, including corticosteroid, nonsteroidal anti-inflammatory drug (NSAID), calcium-channel blocker, and α-adrenergic blockers have been studied. Hollingsworth </offsets><italic><offsets xml_i="6143" xml_f="6148" txt_i="1958" txt_f="1963">et al</offsets></italic><offsets xml_i="6157" xml_f="6296" txt_i="1963" txt_f="2102">. found that there was a significant benefit for both calcium channel blockers and α-adrenergic blockers in improving stone passage rates.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="6329" xml_f="6330" txt_i="2102" txt_f="2103">1</offsets></xref><offsets xml_i="6337" xml_f="6593" txt_i="2103" txt_f="2359">] A subsequent meta-analysis performed by the American Urological Association (AUA)/European Association of Urology (EAU) ureteral stones guidelines panel found that α-adrenergic blockers were superior to nifedipine and may be the preferred agent for MET.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="6626" xml_f="6627" txt_i="2359" txt_f="2360">2</offsets></xref><offsets xml_i="6634" xml_f="6635" txt_i="2360" txt_f="2361">]</offsets></p><p><offsets xml_i="6642" xml_f="6781" txt_i="2362" txt_f="2501">Drugs that expel stones might act by relaxing ureteral smooth muscle through inhibition of calcium channel pumps or α-1 receptor blockade.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6814" xml_f="6815" txt_i="2501" txt_f="2502">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="6855" xml_f="6856" txt_i="2502" txt_f="2503">4</offsets></xref><offsets xml_i="6863" xml_f="6921" txt_i="2503" txt_f="2561">] Tamsulosin is one of the most commonly used α-blockers.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="6954" xml_f="6955" txt_i="2561" txt_f="2562">1</offsets></xref><xref rid="ref3" ref-type="bibr"><offsets xml_i="6995" xml_f="6996" txt_i="2562" txt_f="2563">3</offsets></xref><xref rid="ref5" ref-type="bibr"><offsets xml_i="7036" xml_f="7037" txt_i="2563" txt_f="2564">5</offsets></xref><xref rid="ref6" ref-type="bibr"><offsets xml_i="7077" xml_f="7078" txt_i="2564" txt_f="2565">6</offsets></xref><xref rid="ref7" ref-type="bibr"><offsets xml_i="7118" xml_f="7119" txt_i="2565" txt_f="2566">7</offsets></xref><xref rid="ref8" ref-type="bibr"><offsets xml_i="7159" xml_f="7160" txt_i="2566" txt_f="2567">8</offsets></xref><offsets xml_i="7167" xml_f="7311" txt_i="2567" txt_f="2711">] However, multiple studies have suggested that tamsulosin, terazosin, and doxazosin are equally effective, indicating a possible class effect.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="7344" xml_f="7345" txt_i="2711" txt_f="2712">9</offsets></xref><xref rid="ref10" ref-type="bibr"><offsets xml_i="7386" xml_f="7388" txt_i="2712" txt_f="2714">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="7429" xml_f="7431" txt_i="2714" txt_f="2716">11</offsets></xref><xref rid="ref12" ref-type="bibr"><offsets xml_i="7472" xml_f="7474" txt_i="2716" txt_f="2718">12</offsets></xref><xref rid="ref13" ref-type="bibr"><offsets xml_i="7515" xml_f="7517" txt_i="2718" txt_f="2720">13</offsets></xref><xref rid="ref14" ref-type="bibr"><offsets xml_i="7558" xml_f="7560" txt_i="2720" txt_f="2722">14</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="7601" xml_f="7603" txt_i="2722" txt_f="2724">15</offsets></xref><offsets xml_i="7610" xml_f="7611" txt_i="2724" txt_f="2725">]</offsets></p><p><offsets xml_i="7618" xml_f="7738" txt_i="2726" txt_f="2846">Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms had already been demonstrated.[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="7772" xml_f="7774" txt_i="2846" txt_f="2848">16</offsets></xref><offsets xml_i="7781" xml_f="7805" txt_i="2848" txt_f="2872">] With demonstration of </offsets><italic><offsets xml_i="7813" xml_f="7821" txt_i="2872" txt_f="2880">in vitro</offsets></italic><offsets xml_i="7830" xml_f="7960" txt_i="2880" txt_f="3010"> effects of phosphodiesterase-5 inhibitor (PDE5i) sildenafil, vardenafil, and tadalafil on isolated human ureteral smooth muscle,[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="7994" xml_f="7996" txt_i="3010" txt_f="3012">17</offsets></xref><offsets xml_i="8003" xml_f="8051" txt_i="3012" txt_f="3060">] interest in use of PDE5i as MET has increased.</offsets></p><p><offsets xml_i="8058" xml_f="8434" txt_i="3061" txt_f="3437">Since alpha blockers, especially tamsulosin, are proven in multiple randomized controlled trials and in meta-analysis as well as recommended by EAU and AUA guidelines for use as MET for lower ureteric calculus of size up to 10 mm, role of PDE5i in this scenario is not so clear. Hence, we want to compare the efficacy of tadalafil, a PDE5i with the well-known drug tamsulosin.</offsets></p></sec><sec sec-type="patients|methods" id="sec1-2"><title><offsets xml_i="8496" xml_f="8516" txt_i="3439" txt_f="3459">PATIENTS AND METHODS</offsets></title><p><offsets xml_i="8527" xml_f="9562" txt_i="3460" txt_f="4489">Between December 2014 and February 2016, 123 adult patients (&gt;18 years of age) presenting with distal ureteric stones sized 6–10 mm were randomized using computer-based randomization charts equally into treatment with tamsulosin 0.4 mg once daily (Group A) or tadalafil 10 mg once daily (Group B). An informed and written consent was taken from each patient before enrolment into the study. Ethical clearance was taken from the institutional ethics committee. Stone size (largest transverse diameter) was measured on noncontrast computed tomography scan. Therapy was given for a maximum of 4 weeks. The stone expulsion rate, time to stone expulsion, analgesic use (NSAIDs), number of hospital visits for pain, follow-up and endoscopic treatment, and adverse effects of the drugs were noted. Both groups were further divided into two subgroups based on the stone size, one with stone size ≤8 mm and other with &gt;8 mm size. All outcome parameters were further compared among all subgroups to see any difference based on size if any.</offsets></p><p><offsets xml_i="9569" xml_f="10183" txt_i="4490" txt_f="5104">Patients with solitary kidney, history of previous surgery on same ureter, UTI, deteriorating renal function, fever, hydronephrosis, acute or chronic renal failure, multiple ureteral stones, a history of open surgery or endoscopic procedures in the urinary tract, allergy to tamsulosin or tadalafil, concomitant treatment with α-blockers, calcium antagonists, or nitrates, pregnant or lactating mothers, patients who demanded urgent stone removal were excluded from the study. Primary endpoint of this study was the stone expulsion rate. Statistical analysis was done using Fisher's exact test and Chi-square test.</offsets></p></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="10236" xml_f="10243" txt_i="5106" txt_f="5113">RESULTS</offsets></title><p><offsets xml_i="10254" xml_f="10672" txt_i="5114" txt_f="5532">A total of 124 patients were included in the study and randomized into two equal groups of 62 patients by the use of a computer-generated table. All patients completed the study except one in the tamsulosin group because of developing infected hydronephrosis during the study period. No statistically significant differences were observed regarding patients' age, sex, and stone size distribution between both groups [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="10704" xml_f="10711" txt_i="5532" txt_f="5539">Table 1</offsets></xref><offsets xml_i="10718" xml_f="10720" txt_i="5539" txt_f="5541">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="10768" xml_f="10775" txt_i="5542" txt_f="5549">Table 1</offsets></label><caption><p><offsets xml_i="10795" xml_f="10848" txt_i="5549" txt_f="5602">Demographic information and results of the two groups</offsets></p></caption><graphic xlink:href="UA-10-82-g001"></graphic></table-wrap><p><offsets xml_i="10924" xml_f="11083" txt_i="5603" txt_f="5762">The stone expulsion rate was 73.77% in Group A and 69.35% in Group B. Although this was on the higher side in Group A, but the difference was not significant (</offsets><italic><offsets xml_i="11091" xml_f="11092" txt_i="5762" txt_f="5763">P</offsets></italic><offsets xml_i="11101" xml_f="11301" txt_i="5763" txt_f="5963"> = 0.69). The mean expulsion time from the starting of MET was lower for tamsulosin group (9.38 ± 6.66 days) than for tadalafil group (9.61 ± 7.47 days), but this difference was also not significant (</offsets><italic><offsets xml_i="11309" xml_f="11310" txt_i="5963" txt_f="5964">P</offsets></italic><offsets xml_i="11319" xml_f="11328" txt_i="5964" txt_f="5973"> = 0.78).</offsets></p><p><offsets xml_i="11335" xml_f="11593" txt_i="5974" txt_f="6232">A number of colic episodes and analgesic use (NSAIDs) were significantly higher in tadalafil group than in tamsulosin group (0.96 ± 0.74, 0.62 ± 0.83, 0.010; 11.82 ± 3.34, 9.15 ± 3.80, 0.020), but the number of hospital visits was higher in tadalafil group (</offsets><italic><offsets xml_i="11601" xml_f="11602" txt_i="6232" txt_f="6233">P</offsets></italic><offsets xml_i="11611" xml_f="11620" txt_i="6233" txt_f="6242"> = 0.15).</offsets></p><p><offsets xml_i="11627" xml_f="12009" txt_i="6243" txt_f="6619">When we divided both groups into two subgroups based on the size of the stone, the only significant difference observed was for number of colic episodes and analgesic requirement in patients with stone size &gt;8 mm. Patients in tadalafil group with stone size &gt;8 mm had more colic episodes and they also required significantly more analgesics than patients in tamsulosin group (</offsets><italic><offsets xml_i="12017" xml_f="12018" txt_i="6619" txt_f="6620">P</offsets></italic><offsets xml_i="12027" xml_f="12396" txt_i="6620" txt_f="6989"> = 0.010 and 0.032, respectively). Patients with stone size ≤8 mm, more colic episodes, and analgesic requirements were in tadalafil group, but the difference was not significant. Rest of the primary and secondary outcome parameters compared among all subgroups were found to be in the favor of tamsulosin group, but these differences were statistically insignificant [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="12428" xml_f="12435" txt_i="6989" txt_f="6996">Table 2</offsets></xref><offsets xml_i="12442" xml_f="12444" txt_i="6996" txt_f="6998">].</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="12492" xml_f="12499" txt_i="6999" txt_f="7006">Table 2</offsets></label><caption><p><offsets xml_i="12519" xml_f="12589" txt_i="7006" txt_f="7076">Comparison of primary and secondary outcome parameters among subgroups</offsets></p></caption><graphic xlink:href="UA-10-82-g002"></graphic></table-wrap><p><offsets xml_i="12665" xml_f="12752" txt_i="7077" txt_f="7164">Adverse effects such as headache and dizziness occurred more often in tadalafil group (</offsets><italic><offsets xml_i="12760" xml_f="12761" txt_i="7164" txt_f="7165">P</offsets></italic><offsets xml_i="12770" xml_f="13092" txt_i="7165" txt_f="7484"> &gt; 0.05), these were not significant enough to exclude the patients from the study. Incidence of orthostatic hypotension and backache was almost equal in both groups. Abnormal ejaculation was observed in 9.8% of patients in tamsulosin group and 1.6% of patients in tadalafil group with a highly significant difference (</offsets><italic><offsets xml_i="13100" xml_f="13101" txt_i="7484" txt_f="7485">P</offsets></italic><offsets xml_i="13110" xml_f="13124" txt_i="7485" txt_f="7496"> &lt; 0.001) [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="13156" xml_f="13163" txt_i="7496" txt_f="7503">Table 3</offsets></xref><offsets xml_i="13170" xml_f="13172" txt_i="7503" txt_f="7505">].</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="13220" xml_f="13227" txt_i="7506" txt_f="7513">Table 3</offsets></label><caption><p><offsets xml_i="13247" xml_f="13259" txt_i="7513" txt_f="7525">Side effects</offsets></p></caption><graphic xlink:href="UA-10-82-g003"></graphic></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="13384" xml_f="13394" txt_i="7527" txt_f="7537">DISCUSSION</offsets></title><p><offsets xml_i="13405" xml_f="13532" txt_i="7538" txt_f="7665">Of all urinary tract stones, 20% are ureteral stones, and 70% of these stones are located in the distal portion of the ureter.[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="13566" xml_f="13568" txt_i="7665" txt_f="7667">18</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="13609" xml_f="13611" txt_i="7667" txt_f="7669">19</offsets></xref><offsets xml_i="13618" xml_f="13858" txt_i="7669" txt_f="7909">] In last two to three decades, the introduction and improvement of new, minimally invasive procedures (extracorporeal shock wave lithotripsy and ureteroscopy) for ureteral stones has considerably changed the management of ureteral stones.[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="13892" xml_f="13894" txt_i="7909" txt_f="7911">20</offsets></xref><xref rid="ref21" ref-type="bibr"><offsets xml_i="13935" xml_f="13937" txt_i="7911" txt_f="7913">21</offsets></xref><xref rid="ref22" ref-type="bibr"><offsets xml_i="13978" xml_f="13980" txt_i="7913" txt_f="7915">22</offsets></xref><offsets xml_i="13987" xml_f="13988" txt_i="7915" txt_f="7916">]</offsets></p><p><offsets xml_i="13995" xml_f="14174" txt_i="7917" txt_f="8096">The majority of ureteral calculi can pass spontaneously and intervention is usually not required. It is estimated that 95% of stones up to 4 mm pass spontaneously within 40 days.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="14207" xml_f="14208" txt_i="8096" txt_f="8097">2</offsets></xref><offsets xml_i="14215" xml_f="14440" txt_i="8097" txt_f="8316">] A meta-analysis by the AUA guidelines panel determined that ureteral stones with a diameter of &lt;5 mm will pass in up to 98% of cases. For stones with diameters &gt;7 mm, the overall chance of spontaneous passage is low.[</offsets><xref rid="ref23" ref-type="bibr"><offsets xml_i="14474" xml_f="14476" txt_i="8316" txt_f="8318">23</offsets></xref><xref rid="ref24" ref-type="bibr"><offsets xml_i="14517" xml_f="14519" txt_i="8318" txt_f="8320">24</offsets></xref><xref rid="ref25" ref-type="bibr"><offsets xml_i="14560" xml_f="14562" txt_i="8320" txt_f="8322">25</offsets></xref><offsets xml_i="14569" xml_f="14777" txt_i="8322" txt_f="8524">] A wide range of spontaneous passage rates have been reported, ranging from 71% to 98% for distal ureteral stones &lt;5 mm and 25%–53% for stones measuring 5–10 mm with a mean expulsion time of &gt;10 days.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="14810" xml_f="14811" txt_i="8524" txt_f="8525">2</offsets></xref><xref rid="ref3" ref-type="bibr"><offsets xml_i="14851" xml_f="14852" txt_i="8525" txt_f="8526">3</offsets></xref><offsets xml_i="14859" xml_f="14860" txt_i="8526" txt_f="8527">]</offsets></p><p><offsets xml_i="14867" xml_f="14970" txt_i="8528" txt_f="8631">Most authors recommend that stone passage should not exceed 4–6 weeks due to the risk of renal damage.[</offsets><xref rid="ref25" ref-type="bibr"><offsets xml_i="15004" xml_f="15006" txt_i="8631" txt_f="8633">25</offsets></xref><offsets xml_i="15013" xml_f="15428" txt_i="8633" txt_f="9045">] Conservative management is less appropriate in patients with prolonged partial ureteral obstruction (&gt;4–6 weeks), persisting pain or urinary tract infection. Hence, observation is feasible in informed patients who develop no complications (infection, refractory pain, deterioration of renal function). Both the European (EAU) and AUA guidelines also recommend alpha blockers as a viable option in these cases.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="15461" xml_f="15462" txt_i="9045" txt_f="9046">2</offsets></xref><xref rid="ref3" ref-type="bibr"><offsets xml_i="15502" xml_f="15503" txt_i="9046" txt_f="9047">3</offsets></xref><xref rid="ref26" ref-type="bibr"><offsets xml_i="15544" xml_f="15546" txt_i="9047" txt_f="9049">26</offsets></xref><offsets xml_i="15553" xml_f="15554" txt_i="9049" txt_f="9050">]</offsets></p><p><offsets xml_i="15561" xml_f="15927" txt_i="9051" txt_f="9417">Many medical therapies have been investigated as METs including alpha blockers, calcium channel blockers, corticosteroids, and most recently PDE5i. Alpha blockers are currently the only recommended monotherapy for use as MET. Due to the high likelihood of spontaneous passage of stones up to ~5 mm, MET is less likely to increase the stone-free rate in these cases.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="15960" xml_f="15961" txt_i="9417" txt_f="9418">3</offsets></xref><offsets xml_i="15968" xml_f="16032" txt_i="9418" txt_f="9482">] However, MET reduces the need for analgesics in small stones.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="16065" xml_f="16066" txt_i="9482" txt_f="9483">1</offsets></xref><xref rid="ref3" ref-type="bibr"><offsets xml_i="16106" xml_f="16107" txt_i="9483" txt_f="9484">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="16147" xml_f="16148" txt_i="9484" txt_f="9485">4</offsets></xref><offsets xml_i="16155" xml_f="16156" txt_i="9485" txt_f="9486">]</offsets></p><p><offsets xml_i="16163" xml_f="16346" txt_i="9487" txt_f="9670">In a randomized trial of combination therapy including a corticosteroid with tamsulosin compared with corticosteroid with an antispasmodic fluoroglucine trimetossibenzene, Dellabella </offsets><italic><offsets xml_i="16354" xml_f="16359" txt_i="9670" txt_f="9675">et al</offsets></italic><offsets xml_i="16368" xml_f="16604" txt_i="9675" txt_f="9911">. found an increased expulsion rate (70% vs. 100%), more rapid stone expulsion time (111.1 compared with 65.7 h) and less requirement for analgesia in the group treated with tamsulosin for juxtavesical ureteral stones (around 4–13 mm).[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="16638" xml_f="16640" txt_i="9911" txt_f="9913">20</offsets></xref><offsets xml_i="16647" xml_f="16825" txt_i="9913" txt_f="10091">] In the present study, stone expulsion rate in patients treated with tamsulosin was 73.77% and expulsion time was 9.38 ± 6.66 days which is comparable with the earlier studies.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="16858" xml_f="16859" txt_i="10091" txt_f="10092">1</offsets></xref><xref rid="ref27" ref-type="bibr"><offsets xml_i="16900" xml_f="16902" txt_i="10092" txt_f="10094">27</offsets></xref><offsets xml_i="16909" xml_f="16910" txt_i="10094" txt_f="10095">]</offsets></p><p><offsets xml_i="16917" xml_f="17351" txt_i="10096" txt_f="10530">PDEi are a class of drugs that inhibit the breakdown of cAMP and cGMP, enhancing smooth muscle relaxation. Therefore, PDEi may be able to decrease ureteral spasm and facilitate stone passage. Tadalafil is a selective PDE5i and because of its smooth muscle relaxation property, tadalafil received the US Food and Drug Administration approval for lower urinary tract symptoms with benign prostatic hyperplasia and erectile dysfunction.[</offsets><xref rid="ref28" ref-type="bibr"><offsets xml_i="17385" xml_f="17387" txt_i="10530" txt_f="10532">28</offsets></xref><xref rid="ref29" ref-type="bibr"><offsets xml_i="17428" xml_f="17430" txt_i="10532" txt_f="10534">29</offsets></xref><offsets xml_i="17437" xml_f="17438" txt_i="10534" txt_f="10535">]</offsets></p><p><offsets xml_i="17445" xml_f="17717" txt_i="10536" txt_f="10805">In this study, it was found that the stone expulsion rate and time required with tadalafil were better than historical controls (25%–54% and &gt;10 days) but inferior to tamsulosin (73.77% and 9.38 ± 6.66 days for tamsulosin vs. 69.35% and 9.61 ± 7.47 days for tadalafil: </offsets><italic><offsets xml_i="17725" xml_f="17726" txt_i="10805" txt_f="10806">P</offsets></italic><offsets xml_i="17735" xml_f="17745" txt_i="10806" txt_f="10816"> =0.775).[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="17779" xml_f="17781" txt_i="10816" txt_f="10818">16</offsets></xref><xref rid="ref27" ref-type="bibr"><offsets xml_i="17822" xml_f="17824" txt_i="10818" txt_f="10820">27</offsets></xref><offsets xml_i="17831" xml_f="17960" txt_i="10820" txt_f="10949">] The reason behind this lower efficacy of tadalafil may be due to the predominance of alpha receptors than PDE5 in lower ureter.</offsets></p><p><offsets xml_i="17967" xml_f="18412" txt_i="10950" txt_f="11395">A ureteral stone usually causes severe colicky pain as a result of an increase in intraureteral pressure above the site of ureteral obstruction. At present, NSAIDs and anti-spasmodic drugs are generally used for relieving the pain caused by acute ureteral obstruction. Tamsulosin and tadalafil might reduce the colicky episodes, hence analgesics requirement and hospital visits by relaxing the ureteral smooth muscles and early stone expulsion.[</offsets><xref rid="ref29" ref-type="bibr"><offsets xml_i="18446" xml_f="18448" txt_i="11395" txt_f="11397">29</offsets></xref><xref rid="ref30" ref-type="bibr"><offsets xml_i="18489" xml_f="18491" txt_i="11397" txt_f="11399">30</offsets></xref><offsets xml_i="18498" xml_f="18782" txt_i="11399" txt_f="11683">] In our study, number of colic episodes, analgesics requirement, and number of hospital visits were lower in tamsulosin group than in tadalafil group (0.62 ± 0.83; 9.15 ± 3.80; 0.22 ± 0.51, respectively, for tamsulosin group vs. 0.96 ± 0.74; 11.82 ± 3.34; 0.26 ± 0.39 for tadalafil).</offsets></p><p><offsets xml_i="18789" xml_f="19109" txt_i="11684" txt_f="12001">In our best knowledge, no study till date had compared tamsulosin and tadalafil after dividing them into subgroups based on the stone size. In the present study, it was found that tamsulosin was better than tadalafil for all primary and secondary outcome variables and this difference was more for stones &gt;8 mm sizes.</offsets></p><p><offsets xml_i="19116" xml_f="19401" txt_i="12002" txt_f="12287">No serious side effect occurred in any patient. Headache and dizziness were more common in tamsulosin group while the incidence of backache and orthostatic hypotension was almost similar in both groups. Abnormal ejaculation was significantly higher in tamsulosin group (9.8% vs. 1.6%; </offsets><italic><offsets xml_i="19409" xml_f="19410" txt_i="12287" txt_f="12288">P</offsets></italic><offsets xml_i="19419" xml_f="19512" txt_i="12288" txt_f="12378"> &lt; 0.001). Limitations of this study were small sample size and single-center-based study.</offsets></p></sec><sec sec-type="conclusion" id="sec1-5"><title><offsets xml_i="19568" xml_f="19578" txt_i="12380" txt_f="12390">CONCLUSION</offsets></title><p><offsets xml_i="19589" xml_f="19854" txt_i="12391" txt_f="12656">Medical expulsion therapy using tamsulosin and tadalafil is efficacious and safe for lower ureteric calculus up to 10 mm size. This study showed that although tamsulosin is more effective for stone clearance than tadalafil, but this difference was not significant (</offsets><italic><offsets xml_i="19862" xml_f="19863" txt_i="12656" txt_f="12657">P</offsets></italic><offsets xml_i="19872" xml_f="20075" txt_i="12657" txt_f="12860"> = 0.690). Furthermore, the side effects with tamsulosin were found to be less than that with tadalafil. Further large multicenter randomized controlled trials are needed for validation of these results.</offsets></p><sec id="sec2-1"><title><offsets xml_i="20103" xml_f="20136" txt_i="12861" txt_f="12894">Financial support and sponsorship</offsets></title><p><offsets xml_i="20147" xml_f="20151" txt_i="12895" txt_f="12899">Nil.</offsets></p></sec><sec id="sec2-2" sec-type="COI-statement"><title><offsets xml_i="20210" xml_f="20231" txt_i="12901" txt_f="12922">Conflicts of interest</offsets></title><p><offsets xml_i="20242" xml_f="20277" txt_i="12923" txt_f="12958">There are no conflicts of interest.</offsets></p></sec></sec></body><back><ack><title>Acknowledgment</title><p>We acknowledge the support of Er. Rajesh Goyal, Dr. Chandan Jha, and Dr. Vikram Aggarwal.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollingsworth</surname><given-names>JM</given-names></name><name><surname>Rogers</surname><given-names>MA</given-names></name><name><surname>Kaufman</surname><given-names>SR</given-names></name><name><surname>Bradford</surname><given-names>TJ</given-names></name><name><surname>Saint</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>JT</given-names></name><etal></etal></person-group><article-title>Medical therapy to facilitate urinary stone passage: A meta-analysis</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1171</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17011944</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preminger</surname><given-names>GM</given-names></name><name><surname>Tiselius</surname><given-names>HG</given-names></name><name><surname>Assimos</surname><given-names>DG</given-names></name><name><surname>Alken</surname><given-names>P</given-names></name><name><surname>Buck</surname><given-names>AC</given-names></name><name><surname>Gallucci</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>2007 Guideline for the management of ureteral calculi</article-title><source>Eur Urol</source><year>2007</year><volume>52</volume><fpage>1610</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">18074433</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seitz</surname><given-names>C</given-names></name><name><surname>Liatsikos</surname><given-names>E</given-names></name><name><surname>Porpiglia</surname><given-names>F</given-names></name><name><surname>Tiselius</surname><given-names>HG</given-names></name><name><surname>Zwergel</surname><given-names>U</given-names></name></person-group><article-title>Medical therapy to facilitate the passage of stones: What is the evidence?</article-title><source>Eur Urol</source><year>2009</year><volume>56</volume><fpage>455</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">19560860</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liatsikos</surname><given-names>EN</given-names></name><name><surname>Katsakiori</surname><given-names>PF</given-names></name><name><surname>Assimakopoulos</surname><given-names>K</given-names></name><name><surname>Voudoukis</surname><given-names>T</given-names></name><name><surname>Kallidonis</surname><given-names>P</given-names></name><name><surname>Constantinides</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Doxazosin for the management of distal-ureteral stones</article-title><source>J Endourol</source><year>2007</year><volume>21</volume><fpage>538</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17523910</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lojanapiwat</surname><given-names>B</given-names></name><name><surname>Kochakarn</surname><given-names>W</given-names></name><name><surname>Suparatchatpan</surname><given-names>N</given-names></name><name><surname>Lertwuttichaikul</surname><given-names>K</given-names></name></person-group><article-title>Effectiveness of low-dose and standard-dose tamsulosin in the treatment of distal ureteric stones: A randomized controlled study</article-title><source>J Int Med Res</source><year>2008</year><volume>36</volume><fpage>529</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">18534135</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Huang</surname><given-names>SW</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name></person-group><article-title>Efficacy of an alpha1 blocker in expulsive therapy of lower ureteral stones</article-title><source>J Endourol</source><year>2008</year><volume>22</volume><fpage>41</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18315472</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Matsushima</surname><given-names>H</given-names></name><name><surname>Morimoto</surname><given-names>H</given-names></name><name><surname>Tsuzaka</surname><given-names>Y</given-names></name><name><surname>Homma</surname><given-names>Y</given-names></name></person-group><article-title>Efficacy of low dose tamsulosin in medical expulsive therapy for ureteral stones in Japanese male patients: A randomized controlled study</article-title><source>Int J Urol</source><year>2010</year><volume>17</volume><fpage>462</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">20202002</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Ansari</surname><given-names>A</given-names></name><name><surname>Al-Naimi</surname><given-names>A</given-names></name><name><surname>Alobaidy</surname><given-names>A</given-names></name><name><surname>Assadiq</surname><given-names>K</given-names></name><name><surname>Azmi</surname><given-names>MD</given-names></name><name><surname>Shokeir</surname><given-names>AA</given-names></name></person-group><article-title>Efficacy of tamsulosin in the management of lower ureteral stones: A randomized double-blind placebo-controlled study of 100 patients</article-title><source>Urology</source><year>2010</year><volume>75</volume><fpage>4</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20109697</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>E</given-names></name><name><surname>Batislam</surname><given-names>E</given-names></name><name><surname>Basar</surname><given-names>MM</given-names></name><name><surname>Tuglu</surname><given-names>D</given-names></name><name><surname>Ferhat</surname><given-names>M</given-names></name><name><surname>Basar</surname><given-names>H</given-names></name></person-group><article-title>The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones</article-title><source>J Urol</source><year>2005</year><volume>173</volume><fpage>2010</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">15879806</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehri</surname><given-names>AA</given-names></name><name><surname>Ather</surname><given-names>MH</given-names></name><name><surname>Abbas</surname><given-names>F</given-names></name><name><surname>Biyabani</surname><given-names>SR</given-names></name></person-group><article-title>Preliminary study of efficacy of doxazosin as a medical expulsive therapy of distal ureteric stones in a randomized clinical trial</article-title><source>Urology</source><year>2010</year><volume>75</volume><fpage>1285</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20189226</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Sarkari</surname><given-names>A</given-names></name><name><surname>Lavania</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones</article-title><source>Urology</source><year>2009</year><volume>73</volume><fpage>706</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19193417</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedro</surname><given-names>RN</given-names></name><name><surname>Hinck</surname><given-names>B</given-names></name><name><surname>Hendlin</surname><given-names>K</given-names></name><name><surname>Feia</surname><given-names>K</given-names></name><name><surname>Canales</surname><given-names>BK</given-names></name><name><surname>Monga</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Alfuzosin stone expulsion therapy for distal ureteral calculi: A double-blind, placebo controlled study</article-title><source>J Urol</source><year>2008</year><volume>179</volume><fpage>2244</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18423747</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>LH</given-names></name><name><surname>Tai</surname><given-names>DC</given-names></name><name><surname>Fung</surname><given-names>BT</given-names></name><name><surname>Li</surname><given-names>JC</given-names></name><name><surname>Fan</surname><given-names>CW</given-names></name><name><surname>Li</surname><given-names>MK</given-names></name></person-group><article-title>Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10 mm: A prospective randomized controlled trial</article-title><source>Int J Urol</source><year>2011</year><volume>18</volume><fpage>510</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">21592234</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>SG</given-names></name><name><surname>Lu</surname><given-names>JL</given-names></name><name><surname>Hui</surname><given-names>JH</given-names></name></person-group><article-title>Comparing efficacy of a1D-receptor antagonist naftopidil and a1A/D-receptor antagonist tamsulosin in management of distal ureteral stones</article-title><source>World J Urol</source><year>2011</year><volume>29</volume><fpage>767</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">21845472</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuzaka</surname><given-names>Y</given-names></name><name><surname>Matsushima</surname><given-names>H</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Homma</surname><given-names>Y</given-names></name></person-group><article-title>Naftopidil vs. silodosin in medical expulsive therapy for ureteral stones: A randomized controlled study in Japanese male patients</article-title><source>Int J Urol</source><year>2011</year><volume>18</volume><fpage>792</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21917021</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oelke</surname><given-names>M</given-names></name><name><surname>Giuliano</surname><given-names>F</given-names></name><name><surname>Mirone</surname><given-names>V</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Viktrup</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial</article-title><source>Eur Urol</source><year>2012</year><volume>61</volume><fpage>917</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">22297243</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gratzke</surname><given-names>C</given-names></name><name><surname>Uckert</surname><given-names>S</given-names></name><name><surname>Kedia</surname><given-names>G</given-names></name><name><surname>Reich</surname><given-names>O</given-names></name><name><surname>Schlenker</surname><given-names>B</given-names></name><name><surname>Seitz</surname><given-names>M</given-names></name><etal></etal></person-group><article-title><italic>In vitro</italic> effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: A basic research approach</article-title><source>Urol Res</source><year>2007</year><volume>35</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">17102958</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Küpeli</surname><given-names>B</given-names></name><name><surname>Irkilata</surname><given-names>L</given-names></name><name><surname>Gürocak</surname><given-names>S</given-names></name><name><surname>Tunç</surname><given-names>L</given-names></name><name><surname>Kiraç</surname><given-names>M</given-names></name><name><surname>Karaoglan</surname><given-names>U</given-names></name><etal></etal></person-group><article-title>Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?</article-title><source>Urology</source><year>2004</year><volume>64</volume><fpage>1111</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15596181</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carstensen</surname><given-names>HE</given-names></name><name><surname>Hansen</surname><given-names>TS</given-names></name></person-group><article-title>Stones in the ureter</article-title><source>Acta Chir Scand Suppl</source><year>1973</year><volume>433</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">4513510</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellabella</surname><given-names>M</given-names></name><name><surname>Milanese</surname><given-names>G</given-names></name><name><surname>Muzzonigro</surname><given-names>G</given-names></name></person-group><article-title>Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones</article-title><source>J Urol</source><year>2003</year><volume>170</volume><issue>6 Pt 1</issue><fpage>2202</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">14634379</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segura</surname><given-names>JW</given-names></name><name><surname>Preminger</surname><given-names>GM</given-names></name><name><surname>Assimos</surname><given-names>DG</given-names></name><name><surname>Dretler</surname><given-names>SP</given-names></name><name><surname>Kahn</surname><given-names>RI</given-names></name><name><surname>Lingeman</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association</article-title><source>J Urol</source><year>1997</year><volume>158</volume><fpage>1915</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">9334635</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>M</given-names></name><name><surname>Resnick</surname><given-names>MI</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Walsh</surname><given-names>PC</given-names></name><name><surname>Retik</surname><given-names>AB</given-names></name><name><surname>Vaughan</surname><given-names>ED</given-names></name></person-group><article-title>Urinary lithiasis: Etiology, diagnosis, and medical management</article-title><source>Campbell's Urology</source><year>2002</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Saunders</publisher-name><fpage>3227</fpage><lpage>92</lpage></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stoller</surname><given-names>ML</given-names></name><name><surname>Bolton</surname><given-names>DM</given-names></name></person-group><article-title>Smith's Urology</article-title><year>2000</year><publisher-loc>San Francisco</publisher-loc><publisher-name>Lange Medical Book/McGraw-Hill</publisher-name><fpage>291</fpage><lpage>320</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>AI</given-names></name><name><surname>Shetty</surname><given-names>SD</given-names></name><name><surname>Awad</surname><given-names>RM</given-names></name><name><surname>Patel</surname><given-names>KP</given-names></name></person-group><article-title>Prognostic factors in the conservative treatment of ureteric stones</article-title><source>Br J Urol</source><year>1991</year><volume>67</volume><fpage>358</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">2032074</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiselius</surname><given-names>HG</given-names></name><name><surname>Ackermann</surname><given-names>D</given-names></name><name><surname>Alken</surname><given-names>P</given-names></name><name><surname>Buck</surname><given-names>C</given-names></name><name><surname>Conort</surname><given-names>P</given-names></name><name><surname>Gallucci</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Guidelines on urolithiasis</article-title><source>Eur Urol</source><year>2001</year><volume>40</volume><fpage>362</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11713390</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Turk</surname><given-names>C</given-names></name><name><surname>Knoll</surname><given-names>T</given-names></name><name><surname>Petrik</surname><given-names>A</given-names></name></person-group><article-title>Guidelines on Urolithiasis</article-title><source>European Association of Urology</source><year>2014</year><date-in-citation>Lsst accessed on 2014 Dec 01</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.uroweb.org/gls/pdf/%Urolithisis_LR.pdf">http://www.uroweb.org/gls/pdf/%Urolithisis_LR.pdf</uri></comment></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Jayant</surname><given-names>K</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name></person-group><article-title>Comparative efficacy of tamsulosin versus tamsulosin with tadalafil in combination with prednisolone for the medical expulsive therapy of lower ureteric stones: A randomized trial</article-title><source>Korean J Urol</source><year>2014</year><volume>55</volume><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">24648875</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabsigh</surname><given-names>R</given-names></name><name><surname>Seftel</surname><given-names>AD</given-names></name><name><surname>Rosen</surname><given-names>RC</given-names></name><name><surname>Porst</surname><given-names>H</given-names></name><name><surname>Ahuja</surname><given-names>S</given-names></name><name><surname>Deeley</surname><given-names>MC</given-names></name><etal></etal></person-group><article-title>Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction</article-title><source>Urology</source><year>2006</year><volume>68</volume><fpage>689</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">17070333</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setter</surname><given-names>SM</given-names></name><name><surname>Iltz</surname><given-names>JL</given-names></name><name><surname>Fincham</surname><given-names>JE</given-names></name><name><surname>Campbell</surname><given-names>RK</given-names></name><name><surname>Baker</surname><given-names>DE</given-names></name></person-group><article-title>Phosphodiesterase 5 inhibitors for erectile dysfunction</article-title><source>Ann Pharmacother</source><year>2005</year><volume>39</volume><fpage>1286</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">15941818</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coll</surname><given-names>DM</given-names></name><name><surname>Varanelli</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>RC</given-names></name></person-group><article-title>Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT</article-title><source>AJR Am J Roentgenol</source><year>2002</year><volume>178</volume><fpage>101</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">11756098</pub-id></element-citation></ref></ref-list></back></article>